SOTRADECOL
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SOTRADECOL (SOTRADECOL).
Sotradecol (sodium tetradecyl sulfate) is a sclerosing agent that acts by irritating the intimal endothelium of veins, causing inflammation, thrombosis, and subsequent fibrosis, leading to occlusion of the treated vein.
| Metabolism | Sodium tetradecyl sulfate is primarily metabolized in the liver via sulfation and glucuronidation, with involvement of hepatic enzymes such as sulfotransferases and UDP-glucuronosyltransferases (UGTs). |
| Excretion | Primarily renal; <1% recovered as unchanged drug in urine; majority eliminated as metabolites via bile into feces |
| Half-life | Terminal elimination half-life approximately 5-6 hours; clinical effect persists longer due to local action at injection site |
| Protein binding | >90% bound to plasma proteins, primarily albumin |
| Volume of Distribution | 0.15-0.3 L/kg; reflects limited distribution primarily to plasma and interstitial space |
| Bioavailability | Not applicable; administered via intradermal, intravenous, or endoscopic injection; not intended for oral administration |
| Onset of Action | Intravenous or intradermal injection: within minutes to 1 hour for variceal sclerosis; maximum effect at 2-4 weeks post-sclerotherapy |
| Duration of Action | Duration of sclerosing effect lasts weeks to months; complete obliteration of varicose veins may require multiple treatments; clinical improvement sustained for years if treated adequately |
0.5 mL per injection site, multiple sites per session; maximum volume 10 mL per session; intravenous (sclerotherapy) administration; frequency every 4-6 weeks.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment provided in labeling; not studied in renal impairment; use caution in severe impairment. |
| Liver impairment | No specific dose adjustment provided in labeling; caution in Child-Pugh class C due to potential for acute hepatic necrosis. |
| Pediatric use | Safety and efficacy not established in pediatric patients (age <18 years). |
| Geriatric use | No specific dose adjustment required; consider comorbidities and overall health status. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SOTRADECOL (SOTRADECOL).
| Breastfeeding | Unknown excretion in human milk. Due to low systemic absorption after local injection, risk to breastfed infant is likely low. Caution recommended; M/P ratio not established. |
| Teratogenic Risk | FDA Pregnancy Category C. No adequate human studies; animal studies show fetal harm. Use only if benefit outweighs risk. First trimester: potential teratogenicity. Second/third trimester: risk of fetal bradycardia, arrhythmias, or death due to systemic absorption if injected near cervix. |
| Fetal Monitoring |
■ FDA Black Box Warning
Sotradecol injection is contraindicated for the treatment of patients with underlying arterial disease or with known allergy to the drug. Severe adverse reactions including anaphylaxis, pulmonary embolism, and tissue necrosis have been reported.
| Serious Effects |
Known allergy to sodium tetradecyl sulfate; acute thrombophlebitis; severe chronic venous insufficiency; arterial disease; uncontrolled diabetes mellitus; sepsis; pregnancy; breastfeeding; incompetent perforating veins.
| Precautions | Anaphylactic reactions; arterial injection causing tissue necrosis; pulmonary embolism; allergy to the drug; use with caution in patients with thrombophlebitis, hypercoagulable states, or chronic obstructive pulmonary disease; avoid extravasation. |
Loading safety data…
| Monitor maternal vital signs during and after administration. Fetal heart rate monitoring recommended if injected near cervix due to risk of uterine hypertonus or fetal bradycardia. |
| Fertility Effects | No human data on fertility effects. Animal studies showed no adverse effects on fertility at systemic doses similar to human exposure. |